Pharmacokinetics and administration of colony-stimulating factorsPETROS, W. P.Pharmacotherapy. 1992, Vol 12, Num 2, pp 32S-38S, issn 0277-0008, 2Article

Hematopoietic colony-stimulating factos and dose intensityPETROS, W. P; PETERS, W. P.Seminars in oncology. 1993, Vol 20, Num 1, pp 94-99, issn 0093-7754Article

Cost implications of haematopoietic growth factors in the BMT settingPETROS, W. P; PETERS, W. P.Bone marrow transplantation. Supplement (Basingstoke). 1993, Vol 11, Num 2, pp 36-38, issn 0951-3078Conference Paper

Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell supportRIZZIERI, D. A; VREDENBURGH, J. J; AFFRONTI, M. L et al.Journal of clinical oncology. 1999, Vol 17, Num 10, pp 3064-3074, issn 0732-183XArticle

A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignanciesHUSSEIN, A. M; PETROS, W. P; GUPTON, C et al.Cancer chemotherapy and pharmacology. 1996, Vol 37, Num 6, pp 561-568, issn 0344-5704Article

Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trialPETROS, W. P; CHANEY, S. G; SMITH, D. C et al.Cancer chemotherapy and pharmacology. 1993, Vol 33, Num 4, pp 347-354, issn 0344-5704Article

Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjectsRELLING, M. V; CHERRIE, J; SCHELL, M. J et al.Clinical pharmacology and therapeutics. 1991, Vol 50, Num 3, pp 308-313, issn 0009-9236Article

Clinical pharmacology of filgrastim following high-dose chemotherapy and autologous bone marrow transplantationPETROS, W. P; RABINOWITZ, J; STUART, A et al.Clinical cancer research. 1997, Vol 3, Num 5, pp 705-711, issn 1078-0432Article

Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal diseasePERRY, J. J; FLEMING, R. A; ROCCO, M. V et al.Bone marrow transplantation (Basingstoke). 1999, Vol 23, Num 8, pp 839-842, issn 0268-3369Article

Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancerWILCZYNSKI, S. W; ERASMUS, J. J; PETROS, W. P et al.American journal of respiratory and critical care medicine. 1998, Vol 157, Num 2, pp 565-573, issn 1073-449XArticle

Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liverFISHER, D. C; VREDENBURGH, J. J; PETROS, W. P et al.Bone marrow transplantation (Basingstoke). 1998, Vol 21, Num 2, pp 117-122, issn 0268-3369Article

Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed and relapsed acute lymphocytic leukemiaEVANS, W. E; RODMAN, J. H; RELLING, M. V et al.The Journal of pharmacology and experimental therapeutics. 1992, Vol 260, Num 1, pp 71-77, issn 0022-3565Article

Variability in teniposide plasma protein binding is correlated with serum albumin concentrationsPETROS, W. P; RODMAN, J. H; RELLING, M. V et al.Pharmacotherapy. 1992, Vol 12, Num 4, pp 273-277, issn 0277-0008Article

Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancerGILBERT, C. J; PETROS, W. P; PETERS, W. P et al.Cancer chemotherapy and pharmacology. 1998, Vol 42, Num 6, pp 497-503, issn 0344-5704Article

A phase I trial of recombinant human interleukin-1β (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantationELKORDY, M; CRUMP, M; CONIGLIO, D et al.Bone marrow transplantation (Basingstoke). 1997, Vol 19, Num 4, pp 315-322, issn 0268-3369Article

Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograftHARE, C. B; ELION, G. B; COLVIN, O. M et al.Cancer chemotherapy and pharmacology. 1997, Vol 40, Num 5, pp 409-414, issn 0344-5704Article

Artifactual hypoglycemia associated with hematopoietic cytokinesASTLES, J. R; PETROS, W. P; PETERS, W. P et al.Archives of pathology & laboratory medicine (1976). 1995, Vol 119, Num 8, pp 713-716, issn 0363-0153Article

High-dose chemotherapy-induced platelet defect : inhibition of platelet signal transduction pathwaysKAROLAK, L; CHANDRA, A; KHAN, W et al.Molecular pharmacology. 1993, Vol 43, Num 1, pp 37-44, issn 0026-895XArticle

Pharmacokinetics of continuous-infusion amsacrine and teniposide for the treatment of relapsed childhood acute nonlymphocytic leukemiaPETROS, W. P; RODMAN, J. H; MIRRO, J. JR et al.Cancer chemotherapy and pharmacology. 1991, Vol 27, Num 5, pp 397-400, issn 0344-5704, 4 p.Article

Phase I/II trial of intravenous Doxil® and whole abdomen hyperthermia in patients with refractory ovarian cancerALVAREZ SECORD, A; JONES, E. L; PROSNITZ, L. R et al.International journal of hyperthermia. 2005, Vol 21, Num 4, pp 333-347, issn 0265-6736, 15 p.Article

Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignanciesOCHOA, L; HURWITZ, H. I; HOFFMAN, C et al.Annals of oncology. 2000, Vol 11, Num 10, pp 1313-1322, issn 0923-7534Article

Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer : a phase II trialSUTTON, L. M; WARMUTH, M. A; PETROS, W. P et al.Cancer chemotherapy and pharmacology. 1997, Vol 40, Num 4, pp 335-341, issn 0344-5704Article

Changes in plasma transforming growth factor beta in response to high-dose chemotherapy for stage II breast cancer : possible implications for the prevention of hepatic veno-occlusive disease and pulmonary drug toxicityMURASE, T; ANSCHER, M. S; PETROS, W. P et al.Bone marrow transplantation (Basingstoke). 1995, Vol 15, Num 2, pp 173-178, issn 0268-3369Article

Characterization of endogenous cytokine concentrations after high-dose chemotherapy with autologous bone marrow supportRABINOWITZ, J; PETROS, W. P; STUART, A. R et al.Blood. 1993, Vol 81, Num 9, pp 2452-2459, issn 0006-4971Article

Two instruments to determine activated partial thromboplastin time : Implications for heparin monitoringTAYLOR, C. T; PETROS, W. P; ORTEL, T. L et al.Pharmacotherapy. 1999, Vol 19, Num 4, pp 383-387, issn 0277-0008Conference Paper